Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

Completed · Phase 1

Conditions studied: Alzheimer Disease

In brief

The purpose of the study is to find out if the plasma concentration of galantamine extended release is changed when BMS-708163 is administered at the same time.

Key facts

Study ID

NCT01039194

Run by

Bristol-Myers Squibb

People needed

18

Starts

2010-01-01

Expected to finish

2010-04-01

Last updated by the study team

2011-01-25

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Healthy men and postmenopausal women

You may not qualify if…

• Gastrointestinal disorders
• Bleeding disorders
• Peptic ulcer disease
• Cholecystectomy
• Seizure disorder
• Asthma
• Chronic obstructive pulmonary disease
• Urinary tract obstruction
• Cardiac conduction abnormalities, including but not limited to "sick sinus syndrome" and those with unexplained syncopal episodes
• Inability to tolerate oral medication
• Inability to be venipunctured and/or tolerate venous access

Where it is running

• Parexel International - Baltimore Epcu — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.